安徽医科大学国际教育学院教案与讲稿 Poor Extensive Untrafast Drug-metabolizing enzyme genotype 2. Some drugs have such a wide therapeutic range that individualizing the dose is not important 3. Ethnic differences in mutant alleles produce ethnic differences in drug responses 4. Different ethnic populations may need different dose 5.High frequency of CYP2D6 variants in Caucasians Nortriptyfine dosing (mg) 50 150 500 Population-based dosing 00101 0.5 CYP2D6 CYP206 CYP2D6 CYP2D6 Homozygous Heterozygous Two normal Duplicated Deletion Deletion alleles Mutiplied Frameshift Frameshift Stop codons Stop codons 6.Case Report-CYP2D6 ultra rapid metabolizer 7.Metoprolol plasma concentration and CYP2D6 genetic polymorphism 100 Con ditference:60X 80 70 60 50. 20 14.2 40 13 39 UM EM EM/het. 100 100 Dose [mg] 8.High frequency of CYP2C19 variants in Chinese 9 TGN accumulation and 6-MP toxicity related to TPMT genotype 1D 0 m/m mw whw [PHARMACOGENETIC PRINCIPLES AND DISCUSS] 5min 1.Genetic tests identify DNA mutations of childhood leukemia.enabling physicians to choose the treatment that fits it precisely 2. Pharmacogenetic Principles 4安徽医科大学国际教育学院教案与讲稿 4 2. Some drugs have such a wide therapeutic range that individualizing the dose is not important 3. Ethnic differences in mutant alleles produce ethnic differences in drug responses 4. Different ethnic populations may need different dose 5. High frequency of CYP2D6 variants in Caucasians 6. Case Report -CYP2D6 ultra rapid metabolizer 7. Metoprolol plasma concentration and CYP2D6 genetic polymorphism 8. High frequency of CYP2C19 variants in Chinese 9. TGN accumulation and 6-MP toxicity related to TPMT genotype [PHARMACOGENETIC PRINCIPLES AND DISCUSS] 5min 1. Genetic tests identify DNA mutations of childhood leukemia, enabling physicians to choose the treatment that fits it precisely. 2. Pharmacogenetic Principles